
Valitse etikettisi
näkyy suoraan injektiopullossaLaboratorioraportti
PDF- Testattu
- Tamoxifen (Nolvadex) 20mg × 100 Tabs
- Laboratorio
- Analiza Białek
- Päivämäärä
- October 2026
- Tulos
- 20.34 mg per tablet (20 mg label)
- Tilauksen nro
- Salasana
Testattu riippumattomasti, tarkistettavissa salasanalla suoraan laboratoriossa.
Tamoxifen (Nolvadex)
PCT & AI
- Laboratoriotestattu
- Lähetetään Saksasta
Tilaus
- DHL seurannalla
- Huomaamaton pakkaus
Yhdellä silmäyksellä
Tamoxifen (Nolvadex) lukuina
Tietopankkimme keskeiset luvut.
Koko tietopankkiartikkeli- Class
- SERMestrogen receptor modulator
- Half-life
- longseveral days
- Use
- Oraldaily
- Sizes
- 10 to 20 mg2 sizes in the shop
What studies show
The source in the lexiconTamoxifen and anastrozole for preventing gynecomastia under bicalutamide (opens in a new tab)
Boccardo et al., Journal of Clinical Oncology, 2005
Arvostelut
Mitä asiakkaat sanovat
Vain todelliset tilaukset, joissa oli Tamoxifen (Nolvadex).
Kaikki arvostelutTietoa
Kaikki aiheesta Tamoxifen (Nolvadex)
Tarkemmat tiedot tulossa pian.
Is tamoxifen approved?
Yes. ChEMBL lists tamoxifen with phase 4 as the highest phase and first approval in 1977. ClinicalTrials.gov lists 685 trials with tamoxifen, almost all on breast cancer, as of 26 October 2026.
How well did tamoxifen prevent gynecomastia in the trial?
114 men received the antiandrogen bicalutamide for 48 weeks, plus placebo, tamoxifen or anastrozole. Gynecomastia developed in 73 percent on placebo, 10 percent on tamoxifen and 51 percent on anastrozole. Breast pain occurred in 39, 6 and 27 percent.
Why was anastrozole weaker?
Anastrozole lowers the production of estrogen, tamoxifen blocks the effect directly at the receptor in the breast gland. In the trial anastrozole did not significantly reduce gynecomastia. A meta-analysis of 9 trials also found no significant benefit for anastrozole.
What does the meta-analysis show?
Nine randomised trials in men on bicalutamide were included. Tamoxifen lowered the risk of gynecomastia and breast pain by 82 percent (relative risk 0.18). Breast radiotherapy lowered the risk of gynecomastia by 52 percent.
Are there data on gynecomastia of unknown cause?
A breast clinic followed 81 men who received tamoxifen over 10 years. In 90.1 percent the gynecomastia resolved completely. There was no control group, so the evidence is limited.
What happened to the hormones?
Testosterone rose in all groups. With tamoxifen free testosterone stayed the same because the binding protein SHBG rose. Adverse events were not more common with tamoxifen than without (35 versus 37 percent).
Vertailut
Miten se vertautuu
Liittyvät
Samankaltaiset tuotteet
Clomid (Clomifen)
Lääkkeet · Post-cycle ja aromataasin estäjät Post-cycle ja aromataasin estäjät
2 kokoa
Aromasin (Exemestane)
Lääkkeet · Post-cycle ja aromataasin estäjät Post-cycle ja aromataasin estäjät
2 kokoa
Arimidex (Anastrozole)
Lääkkeet · Post-cycle ja aromataasin estäjät Post-cycle ja aromataasin estäjät
2 kokoa
Letrozol (Femara)
Lääkkeet · Post-cycle ja aromataasin estäjät Post-cycle ja aromataasin estäjät
2 kokoa
Laboratoriotestattu
Tamoxifen (Nolvadex)
